NA-AION Risk Factors: New Perspectives
Trial ID or NCT#
NCT05305079
Status
RECRUITING
Purpose
The purpose of the study is to use new diagnostic methods (OCT and OCT-A) to shed light on risk factors for the development of NA-AION. The risk factors we are focusing on are comorbidities along with anatomical and vascular characteristics of the optic nerve.
Official Title
Non-Arteritic Anterior Ischemic Optic Neuropathy Risk Factors: New Perspectives
Eligibility Criteria
Ages Eligible for Study: Older than 11 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
- 1. Diagnosis of first episode of NA-AION in study eye with symptom onset within 14 days prior 2. Subject age: Age >10 3. NA-AION diagnosis requires: - disc edema seen and documented by site PI - visual field defect in the study eye consistent with NA-AION and mean deviation worse than 3.0 dB using the study visual field examination protocol - relative afferent pupillary defect (unless the fellow eye had previous NA-AION or other optic nerve or retinal disease that is not exclusionary)
Exclusion Criteria:
- 1. Previous episode of NA-AION in the study eye only 2. Intraocular pressure of >21 mm Hg in the study eye 3. Clinical or pathological evidence of giant cell arteritis 4. Diseases that may affect the optic nerve: glaucoma, multiple sclerosis, Alzheimer disease, and Parkinson disease. Evidence of optic disc drusen and optic nerve hypoplasia are not exclusion criteria given they are important parts of the study. We will not exclude significant retinal diseases, since they may be related to underlying etiologies giving rise to ODD, such as macular degeneration, retinal dystrophies, but eyes with significant retinal diseases will be analyzed separately.
Investigator(s)
Y. Joyce Liao, MD, PhD
Neuro-ophthalmology specialist
Stanford Medicine Professor of Ophthalmology and Professor of Neurology
Shannon Beres, MD
Neuro-ophthalmology specialist,
General neurologist
Clinical Associate Professor, Neurology
Clinical Associate Professor (By courtesy), Ophthalmology
View on ClinicalTrials.gov
